Table 2.
Psychotropic drug use at baseline
| ATC-code | Drug group | Total | Men | Women |
|---|---|---|---|---|
| n = 1037 | n = 268 | n = 769 | ||
| N05A-(N05AN01) + N05BB01 + N05CM06 + R06AD | Antipsychotics and related (incl. PRN) | 230 (22) | 54 (20) | 176 (23) |
| N05A-(N05AN01) + N05BB01 + N05CM06 + R06AD | Antipsychotics and related (excl. PRN) | 219 (21) | 51 (19) | 168 (22) |
| N05A-(N05AN01) | Antipsychotics (incl. PRN) | 175 (17) | 37 (14) | 138 (18) |
| N05A-(N05AN01) | Antipsychotics (excl. PRN) | 168 (16) | 36 (13) | 132 (17) |
| N05BB01 + N05CM06 + R06AD | Drugs related to antipsychotics (incl. PRN) | 72 (7) | 20 (7) | 52 (7) |
| N05BB01 + N05CM06 + R06AD | Drugs related to antipsychotics (excl. PRN) | 67 (6) | 18 (7) | 49 (6) |
| Typical antipsychotics (incl. PRN) | 53 (5) | 12 (4) | 41 (5) | |
| Typical antipsychotics (excl. PRN) | 45 (4) | 9 (3) | 36 (5) | |
| Atypical antipsychotics (incl. PRN) | 135 (13) | 30 (11) | 105 (14) | |
| Atypical antipsychotics (excl. PRN) | 132 (13) | 30 (11) | 102 (13) | |
| N06A | Antidepressants (No PRN use) | 388 (37) | 94 (35) | 294 (38) |
| N06AA | Tricyclic antidepressants | 14 (1) | 3 (1) | 11 (1) |
| N06AB | SSRIs | 299 (29) | 81 (30) | 218 (28) |
| N06AG | MAO-inhibitors | 1 (0) | 0 (0) | 1 (0) |
| N06AX | Other antidepressants | 115 (11) | 20 (7) | 95 (12)* |
| N06AX03 + N06AX11 | Tetracyclic antidepressants | 89 (9) | 17 (6) | 72 (9) |
| N06AX16 + N06AX21 | SNRIs | 28 (3) | 3 (1) | 25 (3) |
| N05BA + N05CD + N05CF + N03AE | BZD and Z-drugs (including PRN) | 404 (39) | 87 (32) | 317 (41)* |
| N05BA + N05CD + N05CF + N03AE | BZD and Z-drugs (excluding PRN) | 304 (29) | 60 (22) | 244 (32)* |
| N05BA | Anxiolytics (incl. PRN) | 161 (16) | 26 (10) | 135 (18)* |
| N05BA | Anxiolytics (excl. PRN) | 99 (10) | 14 (5) | 85 (11)* |
| N05CD + N05CF | Hypnotics, BZD and Z-drugs (incl. PRN) | 312 (30) | 69 (26) | 243 (32) |
| N05CD + N05CF | Hypnotics, BZD and Z-drugs (excl. PRN) | 250 (24) | 52 (19) | 198 (26)* |
| N05CD | Hypnotics, BZD (incl. PRN) | 74 (7) | 20 (7) | 54 (7) |
| N05CD | Hypnotics, BZD (excl. PRN) | 64 (6) | 16 (6) | 48 (6) |
| N05CF | Hypnotics, Z-drugs (incl. PRN) | 239 (23) | 50 (19) | 189 (25)* |
| N05CF | Hypnotics, Z-drugs (excl. PRN) | 186 (18) | 36 (13) | 150 (20)* |
| N03AE | BZD derivatives (incl. PRN) | 6 (1) | 2 (1) | 4 (1) |
| N03AE | BZD derivatives (excl. PRN) | 5 (0) | 1 (0) | 4 (1) |
| Any psychotropic drug | 659 (64) | 159 (59) | 500 (65) | |
| BZD and antidepressants | 186 (18) | 38 (14) | 148 (19) | |
| BZD and antipsychotics | 129 (12) | 25 (9) | 104 (14) | |
| Antidepressants and antipsychotics | 113 (11) | 24 (9) | 89 (12) | |
| BZD, antidepressants and antipsychotics | 65 (6) | 11 (4) | 54 (7) |
Notes: Results are presented as number (%). Significant sex differences are marked with * (p < 0.05). The results of combinations of psychotropic drugs include drugs related to antipsychotics and benzodiazepines. PRN Pro Re Nata (when needed), SSRIs Selective Serotonin Reuptake Inhibitors, MAO Monoamine Oxidase, SNRIs Serotonin-Norepinephrine Reuptake Inhibitors, BZD Benzodiazepines